Probiotics Supplementation in Premature Infants

NCT ID: NCT01379417

Last Updated: 2011-08-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

199 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-11-30

Study Completion Date

2010-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main objective is to assess the nutritional benefit of probiotics supplementation on premature infants growth. As secondary objectives, different parameters related to probiotics tolerance will be measured.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prematurity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Maltodextrin

Maltodextrin

Group Type PLACEBO_COMPARATOR

Probiotic supplementation

Intervention Type DIETARY_SUPPLEMENT

1 capsule per day, from inclusion to 4 or 6 weeks after inclusion

Probiotic B lactis/B longum

Bifidobacterium lactis + Bifidobacterium longum

Group Type ACTIVE_COMPARATOR

Probiotic supplementation

Intervention Type DIETARY_SUPPLEMENT

1 capsule per day, from inclusion to 4 or 6 weeks after inclusion

Probiotic B longum

Bifidobacterium longum

Group Type ACTIVE_COMPARATOR

Probiotic supplementation

Intervention Type DIETARY_SUPPLEMENT

1 capsule per day, from inclusion to 4 or 6 weeks after inclusion

Probiotic B lactis

Bifidobacterium lactis

Group Type ACTIVE_COMPARATOR

Probiotic supplementation

Intervention Type DIETARY_SUPPLEMENT

1 capsule per day, from inclusion to 4 or 6 weeks after inclusion

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Probiotic supplementation

1 capsule per day, from inclusion to 4 or 6 weeks after inclusion

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Gestational age between 26 weeks and 31 weeks
* Birth weight between 700 to 1600 g
* Eutrophic infants (weight between -2 to 2 DS, Usher curves)
* Admitted to one of the participating hospital unit within the 8 days following the birth, the birth date equals the 1st day of life.
* Still on parenteral feeding or infusion on the 5th day of birth


* Digestive disorders \> or equal to 1b on Bell stage
* Severe intra-ventricular haemorrhage (stage 3-4) before 5th day of life.
* Severe malformations or digestive malformations
* No antenatal corticosteroid therapy
* Severe medical or surgical disorder affecting the absorption, digesting and as a result the growth (Hirschsprung disease, lactose intolerance, cow milk protein allergy, mucoviscidosis).
* Parents geographical distance preventing the hospitalization follow-up in the hospital participating unit (geographical distance planned before the infant reaches 1500 g or 32 weeks of gestational age)

Exclusion Criteria

* Enteral/Oral feeding termination during more than 72 hours due to severe digestive disorders (\> or equal to 2a on Bell stage )
* Serious digestive surgery
Minimum Eligible Age

1 Day

Maximum Eligible Age

8 Days

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Société des Produits Nestlé (SPN)

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jean-Charles Picaud, Pr

Role: PRINCIPAL_INVESTIGATOR

Hôpital de la Croix-Rousse

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Service de Nénatologie, Hôpital Femme Mère Enfant

Bron, , France

Site Status

Service de Réanimation Néonatale et Néonatologie, Hôpital de la Croix Rousse

Lyon, , France

Site Status

Service de Réanimation Néonatale, Hôpital Arnaud de Villeneuve

Montpellier, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

References

Explore related publications, articles, or registry entries linked to this study.

Hays S, Jacquot A, Gauthier H, Kempf C, Beissel A, Pidoux O, Jumas-Bilak E, Decullier E, Lachambre E, Beck L, Cambonie G, Putet G, Claris O, Picaud JC. Probiotics and growth in preterm infants: A randomized controlled trial, PREMAPRO study. Clin Nutr. 2016 Aug;35(4):802-11. doi: 10.1016/j.clnu.2015.06.006. Epub 2015 Jul 16.

Reference Type DERIVED
PMID: 26220763 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2006-A00062-49

Identifier Type: OTHER

Identifier Source: secondary_id

04.01.FR.INF

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Probiotics/TPN in the NICU
NCT04977817 COMPLETED